The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Chinese#
Stable vital signs, ECOG:0-1;
Patients have a diagnosis of resectable gallbladder carcinoma by histopathology or cytopathology after radical surgery.
Adequate fresh tumor tissue for genome sequencing and immunohistochemistry test; harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components
Have received following treatment before this study: a. Anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials.
History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years;
Have serious concurrent illness including, but not limited to uncontrolled congestive heart failure(NYHA classification grade III or IV), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure >21.3 Kpa or diastolic blood pressure >13.3 Kpa);
Have ongoing or active serious infection;
Shanghai Jiao Tong University School of Medicine
Lead sponsor
Shanghai Zhongshan Hospital
Collaborator
Ruijin Hospital
Collaborator
RenJi Hospital
Collaborator
Qilu Hospital of Shandong University
Collaborator
The First Affiliated Hospital of Anhui Medical University
Collaborator
Shanghai East Hospital of Tongji University
Collaborator
Changshu Affiliated Hospital of Soochow University
Collaborator
Qinghai People's Hospital
Collaborator
The Second People's Hospital of Baoshan, Yunnan Province
Collaborator
Lanzhou University Second Hospital
Collaborator
The Affiliated Hospital of Inner Mongolia Medical University
Collaborator
The First People's Hospital of Nantong
Collaborator